公开(公告)号：ES2207970T3

公开(公告)日：2004-06-01

申请号：ES99953226

申请日：1999-10-20

Applicant: COGNETIX INC ,  UNIV UTAH RES FOUND ,  SALK INST FOR BIOLOGICAL STUDI

Inventor： CRAIG A GREY ,  GRIFFIN DAVID ,  OLIVERA BALDOMERO M ,  WATKINS MAREN ,  HILLYARD DAVID R ,  IMPERIAL JULITA

IPC: C12N15/09 ,  A61K38/00 ,  A61P1/00 ,  A61P1/04 ,  A61P1/12 ,  A61P7/02 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P9/14 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07K7/08 ,  C07K9/00 ,  C07K14/435 ,  C07K14/575 ,  C12N15/12 ,  A61K38/10 ,  A61K38/16

Abstract: The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr 10 -contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.

公开(公告)号：AT250627T

公开(公告)日：2003-10-15

申请号：AT99953226

申请日：1999-10-20

Applicant: COGNETIX INC ,  UNIV UTAH RES FOUND ,  SALK INST FOR BIOLOGICAL STUDI

Inventor： CRAIG A GREY ,  GRIFFIN DAVID ,  OLIVERA BALDOMERO M ,  WATKINS MAREN ,  HILLYARD DAVID R ,  IMPERIAL JULITA ,  CRUZ LOURDES J ,  WAGSTAFF JOHN D ,  LAYER RICHARD T ,  JONES ROBERT M ,  MCCABE R TYLER

IPC: C12N15/09 ,  A61K38/00 ,  A61P1/00 ,  A61P1/04 ,  A61P1/12 ,  A61P7/02 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P9/14 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07K7/08 ,  C07K9/00 ,  C07K14/435 ,  C07K14/575 ,  C12N15/12 ,  A61K38/10 ,  A61K38/16

Abstract: The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr 10 -contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.

公开(公告)号：HK1039570A1

公开(公告)日：2002-05-03

申请号：HK02101114

申请日：2002-02-15

Applicant: COGNETIX INC ,  UNIV UTAH RES FOUND ,  SALK INST FOR BIOLOGICAL STUDI

Inventor： CRAIG A GREY ,  GRIFFIN DAVID ,  OLIVERA BALDOMERO M ,  WATKINS MAREN ,  HILLYARD DAVID R ,  IMPERIAL JULITA ,  CRUZ LOURDES J ,  WAGSTAFF JOHN D ,  LAYER RICHARD T ,  JONES ROBERT M ,  MCCABE R TYLER

IPC: C12N15/09 ,  A61K38/00 ,  A61P1/00 ,  A61P1/04 ,  A61P1/12 ,  A61P7/02 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P9/14 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07K7/08 ,  C07K9/00 ,  C07K14/435 ,  C07K14/575 ,  C12N15/12 ,  C07K ,  C12N ,  A61K

Abstract: The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr 10 -contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.

公开(公告)号：CA2412077A1

公开(公告)日：2002-01-10

申请号：CA2412077

申请日：2001-06-29

Applicant: COGNETIX INC ,  UNIV UTAH RES FOUND

Inventor： JONES ROBERT M ,  SHEN GREG S ,  WALKER CRAIG S ,  WATKINS MAREN ,  OLIVERA BALDOMERO M ,  SHETTY RESHMA ,  JIMINEZ ELSIE C ,  MCINTOSH J MICHAEL

IPC: C07K14/435 ,  A61K38/17 ,  C12N15/12 ,  G01N33/53

Abstract: The invention relates to relatively short peptides (termed I-conotoxins herein), about 30-50 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include four disulfide bonds.

公开(公告)号：AU735389B2

公开(公告)日：2001-07-05

申请号：AU3886497

申请日：1997-07-21

Applicant: COGNETIX INC ,  UNIV UTAH RES FOUND

Inventor： MCCABE R TYLER ,  ZHOU LI-MING ,  LAYER RICHARD T ,  OLIVERA BALDOMERA M ,  MCINTOSH J MICHAEL

IPC: A61K38/00 ,  A61K35/56 ,  A61P13/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P31/18 ,  A61P37/04 ,  C07K7/08 ,  C07K14/195 ,  C07K14/435 ,  C07K19/00 ,  A61K38/02 ,  C07K5/00 ,  C07K7/00

Abstract: The present invention is directed to the use of conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more gamma-carboxyglutamic acid residues, for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents. Neurologic disorders and psychiatric disorders include epilepsy, convulsions, neurotoxic injury (associated with conditions of hypoxia, anoxia or ischemia which typically follows stroke, cerebrovascular accident, brain or spinal cord trauma, myocardial infarct, physical trauma, drowning, suffocation, perinatal asphyxia, or hypoglycemic events), neurodegeneration (associated with Alzheimer's disease, senile dementia, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson's disease, Huntington's disease, Down's Syndrome, Korsakoff's disease, schizophrenia, AIDS dementia, multi-infarct dementia, Binswanger dementia and neuronal damage associated with uncontrolled seizures), chemical toxicity (such as addiction, morphine tolerance, opiate tolerance, opioid tolerance and barbiturate tolerance), pain (acute, chronic, migraine), anxiety, major depression, manic-depressive illness, obsessive-compulsive disorder, schizophrenia and mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and dystonia (movement disorder), sleep disorder, muscle relaxation and urinary incontinence. In addition, the conantokins are useful for treating HIV infection, ophthalmic indications and memory, learning or cognitive deficits.

公开(公告)号：AU3223500A

公开(公告)日：2000-08-25

申请号：AU3223500

申请日：2000-02-04

Applicant: COGNETIX INC ,  UNIV UTAH RES FOUND

Inventor： WALKER CRAIG ,  SHETTY RESHMA ,  OLIVERA BALDOMERO M ,  HOOPER DAVID ,  JACOBSEN RICHARD ,  STEELE DOUG ,  JONES ROBERT M

IPC: C12N15/09 ,  A61K38/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P29/00 ,  A61P43/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C12N15/12 ,  A61K38/10 ,  C07K14/00

Abstract: The invention relates to relatively short peptides (termed tau-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.

公开(公告)号：AU6520399A

公开(公告)日：2000-05-08

申请号：AU6520399

申请日：1999-10-20

Applicant: COGNETIX INC ,  SALK INSTITUTE THE ,  UNIV UTAH RES FOUND

Inventor： CRAIG A GREY ,  GRIFFEN DAVID ,  OLIVERA BALDOMERO M ,  WATKINS MAREN ,  HILLYARD DAVID R ,  IMPERIAL JULITA ,  CRUZ LOURDES J ,  WAGSTAFF JOHN D ,  LAYER RICHARD T ,  JONES ROBERT M ,  MCINTOSH J MICHAEL ,  MCCABE R TYLER

IPC: C12N15/09 ,  A61K38/00 ,  A61P1/00 ,  A61P1/04 ,  A61P1/12 ,  A61P7/02 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P9/14 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07K7/08 ,  C07K9/00 ,  C07K14/435 ,  C07K14/575 ,  C12N15/12 ,  A61K38/10

Abstract: The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr 10 -contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.

公开(公告)号：AU3886497A

公开(公告)日：1998-02-10

申请号：AU3886497

申请日：1997-07-21

Applicant: COGNETIX INC ,  UNIV UTAH RES FOUND

Inventor： MCCABE R TYLER ,  ZHOU LI-MING ,  LAYER RICHARD T

IPC: A61K38/00 ,  A61K35/56 ,  A61P13/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P31/18 ,  A61P37/04 ,  C07K7/08 ,  C07K14/195 ,  C07K14/435 ,  C07K19/00 ,  A61K38/02 ,  C07K5/00 ,  C07K7/00

Abstract: The present invention is directed to the use of conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more gamma-carboxyglutamic acid residues, for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents. Neurologic disorders and psychiatric disorders include epilepsy, convulsions, neurotoxic injury (associated with conditions of hypoxia, anoxia or ischemia which typically follows stroke, cerebrovascular accident, brain or spinal cord trauma, myocardial infarct, physical trauma, drowning, suffocation, perinatal asphyxia, or hypoglycemic events), neurodegeneration (associated with Alzheimer's disease, senile dementia, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson's disease, Huntington's disease, Down's Syndrome, Korsakoff's disease, schizophrenia, AIDS dementia, multi-infarct dementia, Binswanger dementia and neuronal damage associated with uncontrolled seizures), chemical toxicity (such as addiction, morphine tolerance, opiate tolerance, opioid tolerance and barbiturate tolerance), pain (acute, chronic, migraine), anxiety, major depression, manic-depressive illness, obsessive-compulsive disorder, schizophrenia and mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and dystonia (movement disorder), sleep disorder, muscle relaxation and urinary incontinence. In addition, the conantokins are useful for treating HIV infection, ophthalmic indications and memory, learning or cognitive deficits.

公开(公告)号：CA2261570A1

公开(公告)日：1998-01-29

申请号：CA2261570

申请日：1997-07-21

Applicant: COGNETIX INC ,  UNIV UTAH RES FOUND

Inventor： LAYER RICHARD T ,  ZHOU LI-MING ,  MCCABE R TYLER ,  MCINTOSH J MICHAEL ,  OLIVERA BALDOMERO M

IPC: A61K38/00 ,  A61K35/56 ,  A61P13/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P31/18 ,  A61P37/04 ,  C07K7/08 ,  C07K14/195 ,  C07K14/435 ,  C07K19/00 ,  A61K38/17 ,  A61K38/10

Abstract: The present invention is directed to the use of conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more .gamma.-carboxyglutamic acid residues, for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents. Neurologic disorders and psychiatric disorders include epilepsy, convulsions, neurotoxic injury (associated with conditions of hypoxia, anoxia or ischemia which typically follows stroke, cerebrovascular accident, brain or spinal cord trauma, myocardial infarct, physical trauma, drowning, suffocation, perinatal asphyxia, or hypoglycemic events), neurodegeneration (associated with Alzheimer's disease, senile dementia, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson's disease, Huntington's disease, Down's Syndrome, Korsakoff's disease, schizophrenia, AIDS dementia, multi-infarct dementia, Binswanger dementia and neuronal damage associated with uncontrolled seizures), chemical toxicity (such as addiction, morphine tolerance, opiate tolerance, opioid tolerance and barbiturate tolerance), pain (acute, chronic, migraine), anxiety, major depression, manic-depressive illness, obsessivecompulsive disorder, schizophrenia and mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and dystonia (movement disorder), sleep disorder, muscle relaxation and urinary incontinence. In addition, the conantokins are useful for treating HIV infection, ophthalmic indications and memory, learning or cognitive deficits.

公开(公告)号：WO2004108901A2

公开(公告)日：2004-12-16

申请号：PCT/US2004/017903

申请日：2004-06-04

Applicant: COGNETIX, INC. ,  BULAJ, Grzegorz ,  OLIVERA, Baldomero, M.

Inventor： BULAJ, Grzegorz ,  OLIVERA, Baldomero, M.

IPC: C12N

CPC classification number: G06F19/22 ,  C40B50/02 ,  G01N33/6803 ,  G06F19/14

Abstract: The invention includes a method of assaying phylogenetically related sequences and generating a set of possible nucleic acid or amino acid sequence combinations. Sequences are analyzed to create an alignment and a set of phylogenetically related sequences are selected. The observed residue(s) or indel(s) occupying each position in the alignment of the selected phylogenetically related sequences are identified and this information is used to generate a set of sequence combinations, wherein the set of possible sequence combinations (nucleic acid or polypeptide) is composed of the union of the observed residues or indels identified at each position.

Abstract translation: 本发明包括测定系统发育相关序列并产生一组可能的核酸或氨基酸序列组合的方法。 分析序列以产生比对，并且选择一组与系统发育相关的序列。 识别占据选定的系统发育相关序列比对中每个位置的观察到的残基（或一个或多个），并且该信息用于产生一组序列组合，其中该组可能的序列组合（核酸或多肽 ）由在每个位置识别的观察到的残基或印度人的联合组成。